Save Product
Product Details
FAB
- Comprehensive validation - Validated with various antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
Product Specifications
Assay TypeCompetition-TR-FRETRegulatory StatusRUOReactivityHumanAssay Time1 hrSample volume10 μLProduct Overview
The Human APRIL / TACI Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human APRIL binding to TACI within one hour. It can also be used as a universal detection tool to identify the ability of human APRIL to bind to human TACI.
Storage
1. Store the unopened kit at 2-8°C upon receipt.
2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.
3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.
Materials Provided
IDComponentsSizeFRTP035-C01Human TACI Protein Europium-chelate100 tests/500 testsFRTP035-C02FA Labeled Human APRIL Protein100 tests/500 testsFRTP035-C03Anti-APRIL Neutralizing Antibody30 μg/100 tests 150 μg/500 testsDB-04TR-FRET Sample Dilution Buffer, pH7.450 mL/100 tests & 500 testsDB-05TR-FRET Detection Buffer, pH7.450 mL/100 tests & 500 testsAssay Principles
This Human APRIL / TACI Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human TACI and Europium-chelate labeled streptavidin as the Donor and FA Labeled Human APRIL Protein as the Acceptor.
— When the sample does not contain the inhibitors that block the binding of human APRIL to human TACI, the Donor and Acceptor are in close proximity because of the binding of human APRIL and human TACI. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).
— When the sample contains the inhibitors that block the binding of human APRIL to human TACI, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-TR-FRET
Please refer to DS document for the assay protocol.
In this TR-FRET assay, Human TACI Protein Europium-chelate is used as the Donor and FA Labeled Human APRIL Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human TACI and human APRIL using Anti-APRIL Neutralizing Antibody resulting in a typical IC50 of 0.8215 nM (QC tested).
The kit is suitable for the detection and characterization of APRIL / TACI inhibitors. It was shown that the three Anti-APRIL antibody (Sibeprenlimab) disrupted the interaction, with an IC50 of 0.6833 nM. The anti-TNF-alpha antibody (Adalimumab) showed no significant inhibitory effect in the assay as expected.
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor ligand superfamily member 13
- Category：
- Approved Drugs：
2 Details
- Drugs in Clinical Trials：
30 Details
- Highest Development Stage：
Approved
Contact Us
Drug Candidate Licensing
